Pharmaceutical Technology2d
RCT-2100 by Recode Therapeutics for Cystic Fibrosis: Likelihood of Approval
RCT-2100 is under clinical development by Recode Therapeutics and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition ...
Pharmaceutical Technology2d
Galicaftor by Sionna Therapeutics for Cystic Fibrosis: Likelihood of Approval
Galicaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Mena FN13d
Cystic Fibrosis Market Set For Explosive Growth By 2034, Says Delveinsight
(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...
clinicaladvisor.com6d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
clinicaladvisor.com13d
Alyftrek Gets FDA Approval for Cystic Fibrosis
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
WCBI12d
Heda Lab at MUW is furthering Cystic Fibrosis research
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.